Crossmark

Nintedanib in progressive bronchiolitis obliterans syndrome (BOS) grade 0p-1-2 in lung transplant recipients (INFINITIx-BOS): protocol of a French multicenter randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s13063-025-09314-7

Published Online: 2026-04-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Brugière, Olivier

Hirschi, Sandrine

Reynaud-Gaubert, Martine

Bunel, Vincent

Demant, Xavier

Le Pavec, Jérôme

Falque, Loic

Si Mohammed, Nassima

Tardivon, Coralie

Couffignal, Camille

,
Funding

Funding for this research was provided by:

PHRC Interrégional 2016 in FRANCE (AOR16076)
License Information

Text and Data Mining valid from 2026-04-11

Version of Record valid from 2026-04-13
More Information

Article History

Received: 7 February 2025

Accepted: 16 November 2025

First Online: 11 April 2026

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below